Rose McNulty

A new analysis based on two prospective trials helps clarify the roles of chemotherapy and radiotherapy.

Resmetirom improved MASH and fibrosis consistently across patients regardless of GLP-1 or SGLT2 inhibitor use, with outcomes further enhanced in those who achieved at least 5% weight loss.

Chronic kidney disease now affects more than 788 million adults globally, with rising prevalence, increasing mortality, and substantial contributions to cardiovascular deaths

A study identified 32 dysregulated cytokines and 5 key signaling hubs in idiopathic pulmonary fibrosis (IPF), mapping a complex network of profibrotic pathways that may serve as future therapeutic targets.

A combined assessment of genetic, serologic, and clinical factors may enhance early recognition of patients with RA who are most at risk for ILD.

Modern ibrutinib-based approaches substantially narrow the traditional survival gap observed in CLL.

Remibrutinib demonstrated rapid and sustained symptom relief for chronic spontaneous urticaria in a pooled analysis of REMIX-1 and REMIX-2.

Urticaria symptom reduction with remibrutinib was linked with improved quality of life and sleep for patients with chronic spontaneous urticaria.

The FDA approved selumetinib for adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas based on the KOMET trial.

Remibrutinib shows rapid and sustained relief for chronic spontaneous urticaria, offering a promising oral treatment option for patients.

Plozasiran gains FDA approval as the first treatment for familial chylomicronemia syndrome based on phase 3 PALISADE data.

Guselkumab significantly inhibited structural joint damage and improved symptoms in active PsA through 48 weeks.

A novel RTEL1 nonsense mutation was identified in a woman with multigenerational familial pulmonary fibrosis (PF), expanding the genetic spectrum of telomere-related lung disease and underscoring the importance of genetic testing in suspected inherited interstitial lung disease (ILD).

A wide range of non-invasive tests reliably reflected semaglutide-related improvements in metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.

Routine flow cytometry can reliably track chimeric antigen receptor (CAR) T-cell expansion and persistence in aggressive large B-cell lymphoma (LBCL).

Immunoglobulin heavy chain variable is an important prognostic biomarker in chronic lymphocytic leukemia, but the authors of a new review say its role has yet to be fully understood.

The causes of financial hardship among people with rheumatoid arthritis are not necessarily based on the cost of disease-modifying therapies, according to new research.

A national survey analysis suggests a link between higher Food Inflammation Index scores and metabolic liver disease.

CAR T-cell therapy achieves meaningful responses and survival gains in this aggressive CLL complication.

Diet and metabolic health may have causal effects on MS development, suggesting that a healthy weight, controlling glucose levels, and reducing red meat intake may delay or prevent onset.

Only about 2% of cases of rhabdomyosarcoma primarily arise from the chest wall, and such cases require careful planning.

A vote on the House floor allowed for the government to reopen immediately, but the fight over the extension of ACA subsidies still goes on.

Oncology care advances target social determinants of health through AI, patient education, and community engagement.

An RNA-based therapeutic approach led to transient activation of telomerase activity in a model of pulmonary fibrosis.

Darla Chapman, DNP, ARNP, University of Washington, speaks on the evolution of Alzheimer diagnosis, emphasizing early detection and innovative biomarkers.

Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.

Experts discuss the urgent need for equitable access to cancer care, addressing barriers in treatment delivery and the importance of personalized medicine.

Experts discuss the intersection of innovation, affordability, and access in cancer care, focusing on multiple myeloma and NSCLC advancements.

Brensocatib improves lung structure and reduces exacerbations in non-cystic fibrosis bronchiectasis with or without COPD, according to posters presented at this year's CHEST meeting.

Ritlecitinib significantly improves hair regrowth and reduces psychosocial burdens in patients with alopecia areata, enhancing emotional well-being over time.